Department of Biochemical Analysis, Alicante General University Hospital-Institute for Health and Biomedical Research (ISABIAL), 03010, Alicante, Spain.
Research Laboratory, Alicante General University Hospital-Institute for Health and Biomedical Research (ISABIAL). CIBER Rare Diseases, 03010, Alicante, Spain.
J Endocrinol Invest. 2021 Aug;44(8):1637-1648. doi: 10.1007/s40618-020-01468-2. Epub 2021 Jan 21.
Tumors of the anterior pituitary gland (PTs) are mostly benign tumors with a low prevalence, which has nevertheless increased with advances in brain radiology techniques. Nearly half of PTs are not associated with a clinical endocrine syndrome. These tumors have been indistinctly named non-functioning pituitary adenomas (NFPAs) or silent pituitary tumors (SPTs) and the mechanisms of silencing are not fully known.
To study the frequency and characterize the silent variant of PTs in a large local series, and to assess their pituitary adenohypophyseal gene expression.
This observational, cross-sectional study was performed in a Pituitary Tumor Center of Excellence and involved 268 PTs. After identifying the different subtypes according to the immunohistochemical (IHC) expression of adenohypophyseal hormones, we studied their gene expression by RT-qPCR.
We found that silent tumors were larger and more invasive, but not more proliferative than their functional counterparts. The RT-qPCR complements the IHC typification of PTs, reducing the proportion of null-cell subtype. Finally, some silent PT subtype variants showed lower specific adenohypophyseal hormone gene expression than their functional counterparts, which may contribute to the absence of endocrine manifestations.
This paper highlights the importance of identifying the silent variant of the PTs subtypes. As expected, silent tumors were larger and more invasive than their functioning counterparts. However, there was no difference in the proliferation activity between them. Finally, the lower specific gene expression in the silent than in the functioning counterparts of some PTs subtypes gives insights into the silencing mechanisms of PTs.
垂体前叶肿瘤(PTs)大多为良性肿瘤,发病率较低,但随着脑放射学技术的进步,其发病率有所增加。近一半的 PTs 与临床内分泌综合征无关。这些肿瘤被模糊地命名为无功能性垂体腺瘤(NFPAs)或沉默性垂体肿瘤(SPTs),其沉默机制尚不完全清楚。
在一个大型的本地系列中研究 PTs 中沉默变体的频率和特征,并评估它们的垂体腺垂体基因表达。
这项观察性的、横断面研究是在一个垂体肿瘤卓越中心进行的,共涉及 268 例 PTs。根据腺垂体激素的免疫组织化学(IHC)表达确定不同的亚型后,我们通过 RT-qPCR 研究了它们的基因表达。
我们发现,沉默性肿瘤比功能性肿瘤更大、更具侵袭性,但增殖活性没有更高。RT-qPCR 补充了 PTs 的 IHC 定型,降低了无细胞亚型的比例。最后,一些沉默性 PT 亚型变体的特定腺垂体激素基因表达低于功能性对应物,这可能导致缺乏内分泌表现。
本文强调了识别 PTs 亚型中沉默变体的重要性。与预期的一样,沉默性肿瘤比功能性肿瘤更大、更具侵袭性。然而,它们之间的增殖活性没有差异。最后,一些 PTs 亚型的沉默变体的特定基因表达低于功能性对应物,这为 PTs 的沉默机制提供了新的见解。